65,437 trials
Blepharitis · Meibomianitis · Dry Eye
Primary: Change in Bulbar Conjunctival Hyperemia — -0.61; -0.60 Scores on a scale — p=0.578
Hypertension
Primary: Change From Baseline in Mean Seated Systolic Blood Pressure After 6 Weeks of Nebivolol Monotherapy — -18.2; -12.3 mm Hg
Osteopenia
Primary: Trabecular Bone Volume to Tissue Volume at Distal Radius, Percent Change From Baseline to Month 12 — -1.486; -1.255 Percent Change — p=0.7096
Coronary Artery Disease
Primary: Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose — 93.15; 31.05 Percentage
Fibromyalgia
Primary: The Primary Outcome Measure Was a Composite of Changes From Baseline in Three Co-primary Self Report Measures: Pain Visual Analog Scale (PVAS, Electronic Diaries)…
Anemia · Chronic Kidney Disease
Primary: Safety Profile: Number of Subjects Experiencing at Least 1 Adverse Event — 27; 25; 26 participants
Atrial Fibrillation
Primary: Left Atrial (LA) Remodeling Pre-ablation — 2; 31; 7; 0 participants — p=0.48
Non-small Cell Lung Cancer
Primary: Objective Response Rate of OGX-011 in Combination With Gemcitabine/Platinum-based Regimen — 26 percentage of participants
Fibromyalgia
Primary: Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF). — 20.2; 35.4; 35.3; 79.8…
Postoperative Pain
Primary: Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 3 Days (72 Hours) — 34.8; 40.5 Scores on a scale — p=0.5265
Macular Edema · Retinal Vein Occlusion
Primary: Number of Participants With Ocular Adverse Events in the Study Eye — 51; 64; 63; 60 participants
Inflammation · Pain
Primary: Resolution of Anterior Chamber Cells (ACC). — 62; 33 Eyes — p=<0.001
Primary Biliary Cirrhosis
Primary: Serum Level of Alkaline Phosphatase — 351; 175 U/L — p=<0.0001
Mixed Tumor, Mullerian
Primary: Number of Participants With Overall Response — 8 participants
Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for Fesoterodine Metabolite (5-hydroxymethyltolterodine [5-HMT]) — 30.48; 28.24; 19.64…